Recent Updates
Recently added Catalysts
NBTX Positive Sentiment

Voting Rights and Shares Capital of the Company

Key Takeaway: Nanobiotix, a late-stage clinical biotechnology company, is focused on developing physics-based therapeutic approaches to enhance treatment outcomes. The company is headquartered in Paris and has been publicly listed since 2012. With a robust patent portfolio, Nanobiotix aims to address various medical conditions, including oncology and central nervous system disorders.
Price reaction · baseline $35.15 (2026-09-22 close) · hit after-hours · 1 other NBTX headline(s) in the window, move may be shared
day 0 close
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nanobiotix is pioneering innovative therapeutic approaches.
  • The company has a strong patent portfolio with over 30 families.
  • Nanobiotix is committed to improving treatment outcomes for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+419%
120-day peak, hindsight
Typical move
2.2%
average across 7 past catalysts
Lead asset
NBTXR3
Phase 1 · Radiotherapy

Full Press Release Details

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter .
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
Attachment

Frequently Asked Questions

What is Nanobiotix's focus in biotechnology?

Nanobiotix focuses on developing physics-based therapeutic approaches to improve treatment outcomes.

Where is Nanobiotix headquartered?

Nanobiotix is headquartered in Paris, France.

How many patent families does Nanobiotix own?

Nanobiotix owns more than 30 patent families related to its technologies.

When was Nanobiotix listed on Nasdaq?

Nanobiotix was listed on the Nasdaq Global Select Market in December 2020.

Last updated: Sep 22, 2026